Abstract：Objective：To observe the curative effect of Shengxuening combined with recombinant human erythropoietin (rHuEPO) for renal anemia in patients with maintenance hemodialysis(MHD) and its effect on iron metabolism indexes. Methods：A total of 80 cases of MHD patients with renal anemia were randomly divided into the observation group and the control group， with 40 cases in each group. The control group was given the oral administration of ferrosi succinas and subcutaneous injection with rHuEPO，and the observation group was given the oral administration of Shengxuening tablets and subcutaneous injection with rHuEPO. Before and after treatment， the levels of hemoglobin(Hb)， hematocrit(HCT)， serum ferritin(SF)， transferrin saturation(TAST) and hypersensitive C- reactive protein(hs- CRP) in the two groups were compared；the dosage of rHuEPO in the two groups was recorded. Results：After treatment，the levels of Hb and HCT in blood，serum SF and TAST were increased when compared with those before treatment(P＜0.05)，the levels of serum hs- CRP were decreased(P＜0.05)，and the dosage of rHuEPO was decreased(P＜0.05). After treatment，the levels of Hb and HCT in blood，serum SF and TAST in the observation group were higher than those in the control group(P＜0.05)，the level of serum hs- CRP was lower(P＜0.05)， and the dosage of rHuEPO was fewer(P＜0.05). Conclusion： The therapy of Shengxuening combined with rHuEPO for renal anemia in patients with MHD can effectively increase their Hb levels and improve iron metabolism indexes.